TriSalus Life Sciences, Inc. (NASDAQ:TLSIW – Get Free Report)’s stock price was down 10.7% on Friday . The company traded as low as $1.18 and last traded at $1.25. Approximately 2,700 shares were traded during trading, a decline of 35% from the average daily volume of 4,155 shares. The stock had previously closed at $1.40.
TriSalus Life Sciences Stock Performance
The firm’s 50 day moving average is $1.31 and its two-hundred day moving average is $1.23.
About TriSalus Life Sciences
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Featured Stories
- Five stocks we like better than TriSalus Life Sciences
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- What is the S&P/TSX Index?
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- What Do S&P 500 Stocks Tell Investors About the Market?
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
